Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Geneart AG (OJ:G6A) - GENEART presents the advantages of designed genes and gene synthesis in the programming of vaccines - GENEART will chair an "Industrial Biotechnology" workshop - 'Synthetic Biology 4.0' is the most important international conference on Synthetic Biology, now in its fourth year - GENEART is one of the main sponsors - With DNA synthesis, GENEART provides one of the key technologies for the Synthetic Biology
Regensburg, October 01, 2008 - GENEART AG, the global leader in gene synthesis and specialist in the field of Synthetic Biology will present its work on the "Synthetic Biology 4.0", the largest international conference on Synthetic Biology from October 10 to 12, 2008, in Hong Kong. Using the development of an HIV vaccine as an example, GENEART will elucidate the advantages of designed genes and gene synthesis for the programming of vaccines to the gathered international experts. Additionally, GENEART will moderate the workshop "Industrial Biotechnology". As a main sponsor, GENEART supports the conference which is now in its fourth year. 500 to 700 scientists are expected to come to the conference at the 'University of Science and Technology' in Clear Water Bay, Hong Kong, to discuss the newest developments and insights in the field of Synthetic Biology. Projects to efficiently produce bio-fuels and drugs are of special economic interest.
Similarly to concepts in electrical engineering, the objective in the Synthetic Biology is the development of standardized DNA building blocks, which can be easily combined and which allow the reconstruction of cells, e.g. bacteria into bioreactors. Scientists in the Synthetic Biology thereby aim at the development of bioreactors capable of producing far more complex compounds than currently possible using the conventional methods of classical biotechnology. One way to achieve this is spearheaded by J. Craig Venter' initiative, who envisions to develop bacteria with minimal genomes. In the beginning of this year, the American scientist/entrepreneur has approached this aim with giant steps: Supported by GENEART, he created the first synthetic bacterial genome. Bacteria with minimal genomes could be used as blank cells and thus be equipped with the required additional genes (functional gene clusters) in order to turn them into producer cells. They could e.g. produce bio-fuel from otherwise unused plant components. Right now, British Petroleum and the US Department of Energy invest more than 500M US Dollars in this field. Other projects involve the developments of yeast and bacteria for the production of therapeutics, such as the malaria drug Artemisinin. There are also projects aiming at the production of chemical precursors or polymers, e.g. for the production of spider silk.
GENEART synthesizes the DNA building blocks for the Synthetic Biology, thus providing an important key technology for this new field of research and industry. At the same time, GENEART works together with partners on continuative technologies like the construction of functional gene clusters called operons. This also facilitates and accelerates the development of producer cells. As the global leader in DNA synthesis, GENEART expects to profit above average in the emerging market of this new field of research and industry.
Frank Ostermair Better Orange IR & HV AG Haidelweg 48 81241 Munich Germany Phone: +49-(0)89-8896906-10 Fax: +49-(0)89-8896906-66 info@better-orange.de www.better-orange.de
Legal Information This document may contain estimates, prognoses and opinions about company plans and objectives, products or services, future results, opinions about these results or opinions leading up to these results. All these projections into the future are subject to risk, uncertainty and unforeseeable change outside the control of the GENEART Group. Many factors may lead to actual results, which considerably deviate from the given projections for these results.
About GENEART AG: In 2000, GENEART entered the gene synthesis market and has since become the global market leader. Today, the company is one of the leading specialists in the Synthetic Biology field. Experts at GENEART provide key technologies for the development and production of new therapeutics and vaccines. Customers also take advantage of GENEART services to customize enzyme attributes, such as the attributes of enzymes used as detergent additives, and to construct bacteria, which produce complex biopolymers or break down polymers, such as synthetics, petroleum components, etc. Our production and service spectrum spans a wide range, from the production of synthetic genes according to DIN EN ISO 9001-2000, to the creation of gene libraries in the combinatorial biology, to the development and production of DNA-based biologically active substances. The GENEART AG in Regensburg (Germany) and the subsidiaries GENEART Inc. in Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ more than 190 people. Since May 2006, GENEART is listed on the German Stock Exchange.
Synthetic Biology 4.0: The Synthetic Biology 4.0 is organized by the BioBricks Foundation in cooperation with the Hong Kong University of Science and Technology (HKUST), the University of Hong Kong (HKU) and the Chinese University of Hong Kong (CUHK). The BioBricksTM Foundation is a nonprofit organization. It was established by engineers and scientists to foster the development and responsible use of technologies based on BioBrick standard DNA sequences.
